Compare AbbVie Inc (ABBV) vs abrdn Physical Palladium Shares ETF (PALL) Price & Performance

AbbVie (ABBV) trades at $247.91, up 0.76% on the day, with strong technical momentum as the stock approaches resistance near $249. The company demonstrates solid fundamentals with Q2 2026 EPS beating expectations at $3.65 versus $3.61, driven by robust immunology portfolio growth from Skyrizi and Rinvoq offsetting Humira declines. Revenue reached $61.16B in 2025 with a 71.48% gross margin, though net income margin compressed to 9.8%. Recent positive Phase 2 ovarian cancer data and institutional accumulation signal confidence in the pipeline.

Outlook remains positive with analyst consensus target of $281.33 (13.5% upside) and 71% buy ratings, though elevated P/E of 70.05 reflects growth expectations. Key risks include patent cliffs in the 2030s, competitive pressures, and regulatory uncertainties from drug pricing lawsuits. The dividend aristocrat offers income stability with recent $1.73 payout, but investors should monitor execution of oncology pipeline and debt levels at 50.4% of assets.

PALL trades at $25.05, up 0.64% with bullish technical signals from moving averages. The stock recently underwent a 1:5 split on May 18, 2026. Technical indicators show mixed signals with RSI suggesting mild overbought conditions while ADX indicates strong trend strength. Support and resistance levels cluster around $25-$26, creating a key price zone.

PALL presents a contrarian opportunity as palladium prices remain 47% below January 2026 highs. Supply risks and industrial demand support long-term fundamentals, though the ETF faces commodity price volatility and Federal Reserve policy uncertainty as near-term headwinds.